PHARMACIE BELLANGER : revenue, balance sheet and financial ratios

PHARMACIE BELLANGER is a French company founded 17 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in MONTFORT-LE-GESNOIS (72450), this company of category PME shows in 2019 a revenue of 2.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE BELLANGER (SIREN 508124708)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C N/C 2 723 569 € 2 559 152 € 2 586 958 € 2 679 542 €
Net income 48 999 € 49 023 € 98 369 € 136 715 € 144 024 € 231 664 € 226 327 € 211 037 € 227 306 € 199 693 €
EBITDA N/C N/C N/C N/C N/C N/C 327 434 € 320 014 € 356 444 € 322 433 €
Net margin N/C N/C N/C N/C N/C N/C 8.3% 8.2% 8.8% 7.5%

Revenue and income statement

In 2025, PHARMACIE BELLANGER generates positive net income of 49 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 200 k€ -> 49 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

48 999 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 7%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 85%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

7.408%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

84.652%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

11.8%

Solvency indicators evolution
PHARMACIE BELLANGER

Sector positioning

Debt ratio
7.41 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Good

In 2025, the debt ratio of PHARMACIE BELLANGER (7.41) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
84.65% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Good

In 2025, the financial autonomy of PHARMACIE BELLANGER (84.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 161.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

161.208

Liquidity indicators evolution
PHARMACIE BELLANGER

Sector positioning

Liquidity ratio
161.21 2025
2023
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Average

In 2025, the liquidity ratio of PHARMACIE BELLANGER (161.21) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE BELLANGER

Positioning of PHARMACIE BELLANGER in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of PHARMACIE BELLANGER is estimated at 507 962 € (range 314 863€ - 790 042€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
314k€ 507k€ 790k€
507 962 € Range: 314 863€ - 790 042€
NAF 5 all-time

Valuation method used

Net Income Multiple
48 999 € × 10.4x = 507 963 €
Range: 314 863€ - 790 042€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare PHARMACIE BELLANGER with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about PHARMACIE BELLANGER

What is the revenue of PHARMACIE BELLANGER ?

The revenue of PHARMACIE BELLANGER in 2019 is 2.7 M€.

Is PHARMACIE BELLANGER profitable?

Yes, PHARMACIE BELLANGER generated a net profit of 49 k€ in 2025.

Where is the headquarters of PHARMACIE BELLANGER ?

The headquarters of PHARMACIE BELLANGER is located in MONTFORT-LE-GESNOIS (72450), in the department Sarthe.

Where to find the tax return of PHARMACIE BELLANGER ?

The tax return of PHARMACIE BELLANGER is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE BELLANGER operate?

PHARMACIE BELLANGER operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.